Pfizer (PFE) Stock Buyback History
TTM buyback yield N/A.
PFE
TTM buyback yield
N/A
Shareholder yield (TTM)
N/A
5Y share count change
1.0%
TTM buyback spend
N/A
SBC coverage (TTM)
0.00x
YoY change in spend
N/A
5Y CAGR of spend
N/A
Peak year (2013)
$16.29B
Cumulative spend
$137.76B
TTM metrics calculated from the four most recent reported quarters, ending (reported ).
Key takeaways
- Diluted share count is roughly flat (1.0%) over the last ~5 fiscal years — buybacks are offsetting dilution but not shrinking the float.
Buyback context per fiscal year
Annual repurchases alongside stock-based compensation, diluted share count and the year-over-year change — useful for SBC-coverage and dilution-offset reading at a glance.
| Year | Buybacks | SBC | Net | Shares (dil.) | YoY shares | Buyback yield |
|---|---|---|---|---|---|---|
| 2025 | $0.00 | $0.00 | $0.00 | 5.69B | -0.2% | — |
| 2024 | $0.00 | $877.00M | −$877.00M | 5.70B | -0.2% | — |
| 2023 | $0.00 | $525.00M | −$525.00M | 5.71B | -0.4% | — |
| 2022 | $2.00B | $872.00M | $1.13B | 5.73B | 0.4% | 0.70% |
| 2021 | $0.00 | $1.18B | −$1.18B | 5.71B | 1.3% | — |
| 2020 | $0.00 | $756.00M | −$756.00M | 5.63B | -0.8% | — |
| 2019 | $8.87B | $718.00M | $8.15B | 5.67B | -5.1% | 4.31% |
| 2018 | $12.20B | $949.00M | $11.25B | 5.98B | -1.3% | 5.09% |
| 2017 | $5.00B | $840.00M | $4.16B | 6.06B | -1.6% | 2.44% |
| 2016 | $5.00B | $691.00M | $4.31B | 6.16B | -1.6% | 2.68% |
| 2015 | $6.16B | $669.00M | $5.49B | 6.26B | -2.6% | 3.26% |
| 2014 | $5.00B | $586.00M | $4.41B | 6.42B | -6.8% | 2.69% |
| 2013 | $16.29B | $523.00M | $15.77B | 6.89B | -8.2% | 8.71% |
| 2012 | $8.23B | $481.00M | $7.75B | 7.51B | -4.6% | 4.73% |
| 2011 | $9.00B | $419.00M | $8.58B | 7.87B | -2.5% | 5.75% |
| 2010 | $1.00B | $405.00M | $595.00M | 8.07B | 14.6% | 0.75% |
| 2009 | $0.00 | $349.00M | −$349.00M | 7.04B | 4.4% | — |
| 2008 | $500.00M | $0.00 | $500.00M | 6.75B | -2.7% | 0.44% |
| 2007 | $9.99B | $0.00 | $9.99B | 6.94B | -4.6% | 6.84% |
| 2006 | $6.98B | $0.00 | $6.98B | 7.27B | -1.8% | 3.98% |
| 2005 | $3.80B | $0.00 | $3.80B | 7.41B | -2.7% | 2.34% |
| 2004 | $6.66B | $0.00 | $6.66B | 7.61B | 4.5% | 3.50% |
| 2003 | $13.04B | $0.00 | $13.04B | 7.29B | 16.7% | 5.13% |
| 2002 | $5.00B | $0.00 | $5.00B | 6.24B | -1.9% | 2.82% |
| 2001 | $3.67B | $0.00 | $3.67B | 6.36B | -0.1% | 1.56% |
| 2000 | $1.00B | $0.00 | $1.00B | 6.37B | 0.8% | — |
| 1999 | $2.54B | $0.00 | $2.54B | 6.32B | 60.4% | — |
| 1998 | $2.18B | $0.00 | $2.18B | 3.94B | -0.3% | — |
| 1997 | $586.00M | $0.00 | $586.00M | 3.95B | 2.4% | — |
| 1996 | $27.00M | $0.00 | $27.00M | 3.86B | — | — |
| 1995 | $108.50M | $0.00 | $108.50M | — | — | — |
| 1994 | $511.20M | $0.00 | $511.20M | — | — | — |
| 1993 | $1.02B | $0.00 | $1.02B | — | — | — |
| 1992 | $665.10M | $0.00 | $665.10M | — | — | — |
| 1991 | $463.90M | $0.00 | $463.90M | — | — | — |
| 1990 | $132.20M | $0.00 | $132.20M | — | — | — |
| 1989 | $154.70M | $0.00 | $154.70M | — | — | — |
Cash buyback spend (USD) — annual & quarterly history
Trailing-twelve-month and per-period cash repurchases for Pfizer (PFE) from the consolidated cash flow statement (line: common stock repurchased), in USD as filed.
Cash buyback spend over time for Pfizer (PFE)
Per-period cash repurchases
Cash buyback spend annual + quarterly history for Pfizer (PFE)
| Fiscal year | Period ended | Reported | Buyback Spend | YoY | YoY change |
|---|---|---|---|---|---|
| 2025 | $0 | — | $0 | ||
| 2024 | $0 | — | $0 | ||
| 2023 | $0 | -100.0% | -$2.00B | ||
| 2022 | $2.00B | — | +$2.00B | ||
| 2021 | $0 | — | $0 | ||
| 2020 | $0 | -100.0% | -$8.87B | ||
| 2019 | $8.87B | -27.3% | -$3.33B | ||
| 2018 | $12.20B | +144.0% | +$7.20B | ||
| 2017 | $5.00B | 0.0% | $0 | ||
| 2016 | $5.00B | -18.8% | -$1.16B | ||
| 2015 | $6.16B | +23.2% | +$1.16B | ||
| 2014 | $5.00B | -69.3% | -$11.29B | ||
| 2013 | $16.29B | +98.0% | +$8.06B | ||
| 2012 | $8.23B | -8.6% | -$772.00M | ||
| 2011 | $9.00B | +800.0% | +$8.00B | ||
| 2010 | $1.00B | — | +$1.00B | ||
| 2009 | $0 | -100.0% | -$500.00M | ||
| 2008 | $500.00M | -95.0% | -$9.49B | ||
| 2007 | $9.99B | +43.2% | +$3.02B | ||
| 2006 | $6.98B | +83.8% | +$3.18B | ||
| 2005 | $3.80B | -43.0% | -$2.86B | ||
| 2004 | $6.66B | -48.9% | -$6.38B | ||
| 2003 | $13.04B | +160.9% | +$8.04B | ||
| 2002 | $5.00B | +36.3% | +$1.33B | ||
| 2001 | $3.67B | +264.7% | +$2.66B | ||
| 2000 | $1.00B | -60.5% | -$1.54B | ||
| 1999 | $2.54B | +16.8% | +$365.00M | ||
| 1998 | $2.18B | +271.5% | +$1.59B | ||
| 1997 | $586.00M | +2070.4% | +$559.00M | ||
| 1996 | $27.00M | -75.1% | -$81.50M | ||
| 1995 | $108.50M | -78.8% | -$402.70M | ||
| 1994 | $511.20M | -49.9% | -$508.40M | ||
| 1993 | $1.02B | +53.3% | +$354.50M | ||
| 1992 | $665.10M | +43.4% | +$201.20M | ||
| 1991 | $463.90M | +250.9% | +$331.70M | ||
| 1990 | $132.20M | -14.5% | -$22.50M | ||
| 1989 | $154.70M | — | — |
In 2025, Pfizer (PFE) buyback spend totalled $0.
Across 2015–2025 (10 years), Pfizer buyback spend produced a CAGR of -100.0% – with a net decline across the window.
Pfizer buyback spend peaked at $16.29B in 2013; the latest annual figure is $0 in 2025 (100.0% below peak).
The dataset's maximum buyback spend sits at $16.29B (2013); the minimum reading of $0 dates to 2009.
Pfizer (PFE) sits 8th of 8 Healthcare peers we track on this metric, against a peer median of $2.75B.
Pfizer Buyback Spend 2025: $0
Pfizer buyback spend in 2025 was $0.
Pfizer Buyback Spend 2024: $0
Pfizer buyback spend in 2024 was $0.
Pfizer Buyback Spend 2023: $0
Pfizer buyback spend in 2023 was $0, plunged 100.0% below 2022.
Pfizer Buyback Spend 2022: $2.00B
Pfizer buyback spend in 2022 was $2.00B.
Pfizer Buyback Spend 2021: $0
Pfizer buyback spend in 2021 was $0.
See more financial history for Pfizer (PFE).
Sector peers by buyback spend
Companies in the same sector as Pfizer, ranked by their latest buyback spend.
| Company | Buyback Spend | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $5.95B | Healthcare |
| UnitedHealth Group (UNH) | $5.54B | Healthcare |
| Merck & Co. (MRK) | $5.08B | Healthcare |
| Eli Lilly (LLY) | $4.11B | Healthcare |
| Novo Nordisk (NVO) | $1.39B | Healthcare |
| AbbVie (ABBV) | $980.00M | Healthcare |
| AstraZeneca (AZN) | $719.66M | Healthcare |
| Amgen (AMGN) | $0 | Healthcare |
Share count history
Diluted weighted-average shares drive the EPS denominator and per-share capital-return maths. A falling diluted share count means buybacks are outpacing dilution from stock-based compensation and option exercises.
Diluted vs basic shares (annual)
Year-over-year change in diluted shares
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Dividend & buyback yield over time
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Buybacks vs stock-based compensation
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 0.00×.
Capital allocation mix
How Pfizer splits cash returned to shareholders between dividends and buybacks, plus the headroom on free cash flow that's still available for additional repurchases.
Buybacks vs dividends (share of cash returned)
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $0.00 (TTM FCF − TTM dividends, clamped at zero).
Data & methodology
Where do buyback, dividend and compensation figures come from?
Cash buyback spend (common stock repurchased), dividends paid and stock-based compensation come from Pfizer's consolidated cash flow statements — quarterly 10-Q and annual 10-K SEC filings, in USD as reported.
How are diluted shares and yields calculated?
Diluted weighted-average share counts come from the income statement (EPS denominator). Trailing twelve-month (TTM) aggregates sum the four most recent reported quarters. Buyback and dividend yields divide TTM cash flows by market capitalisation at the latest quarter-end.
How is buyback capacity defined?
Capacity compares TTM repurchases to free cash flow after dividends: operating cash flow minus capital expenditure, minus dividends paid, versus actual buybacks over the same trailing window.
Is this investment advice?
No. Figures are for informational and educational use only. Past buybacks and dividends do not predict future returns.
Frequently asked questions
Does Pfizer buy back its own stock?
Yes, Pfizer (PFE) has repurchased shares in recent periods. See the history table and charts on this page for amounts and trends.
Is Pfizer diluting shareholders?
Compare stock-based compensation (SBC) to buybacks in the chart above. Net effect varies by year; see annual buyback vs SBC bars and the history table.
How has Pfizer's share count changed?
Diluted weighted average shares changed by about 1.0% over roughly five fiscal years (annual income statement data).
What is Pfizer's buyback spend?
Latest reported buyback spend for Pfizer (PFE) is $0 (period ending March 29, 2026).
What is the long-term growth rate of Pfizer buyback spend?
Pfizer (PFE) buyback spend compound annual growth rate is -100.0% over the most recent 10 years available.
When did Pfizer buyback spend hit its highest annual value?
Pfizer buyback spend reached its highest annual value of $16.29B in 2013.
What was Pfizer buyback spend in 2024?
Pfizer (PFE) buyback spend in 2024 was $0.
What was Pfizer buyback spend in 2025?
Pfizer (PFE) buyback spend in 2025 was $0.
Explore more
PFE Overview
Company profile, financial tools, and key metrics
PFE Revenue Counter
Earns $2,008 every second. See per minute, hour, and day.
PFE Earnings Counter
Earns $237.54 per second net profit. See per minute, hour, and day.
PFE Economic Scale
Exceeds Bolivia's GDP. Compare with world economies.
PFE What If Invested
What if you had invested $1,000? See historical returns from any date.
PFE How It Makes Money
Discover visual breakdown of $63.31B in revenue — where it comes from and where it goes.
PFE Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
PFE Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
PFE Daily Price Character
Steady · 46.3% historical win rate (green days). Streaks & record days.
PFE Stock Split History
6 splits on record. Dates, ratios, and cumulative multiple.
PFE Dividend Profile
Yield: 6.67%. Safety: 3/8. See full history.
PFE Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
PFE Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.
PFE Dividend Capture
Historical pre-ex touch stats, gap distribution, after-tax calculator, and a backtest simulator (limit-order vs MOC exit).
PFE Financials
Revenue, EPS, EBITDA, market cap, debt and balance sheet history with annual and quarterly data.